Dec 12, 2022
News
At NGM, we pride ourselves on conducting world-class science and sharing our research efforts with the broader scientific and medical communities.
Dec 07, 2022
NGM Bio Presents Preliminary Data from Phase 1 Monotherapy Dose Escalation Trial of NGM707 in Patients with Advanced or Metastatic Solid Tumors at 2022 ESMO-IO Annual Meeting
Nov 07, 2022
NGM Bio Announces Poster Presentation Featuring Initial Findings from Ph1a Trial of NGM707 in Patients with Advanced Solid Tumors at Upcoming 2022 ESMO-IO Annual Meeting
Nov 04, 2022
NGM Bio Announces Poster Presentation Featuring Preclinical Characterization of NGM936 at Upcoming 2022 ASH Annual Meeting
Nov 03, 2022
NGM Bio Announces Presentation of Post-Hoc Analyses from CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) at The Retina Society Annual Scientific Meeting
Nov 03, 2022
NGM Bio Provides Business Highlights and Reports Third Quarter 2022 Financial Results
Oct 17, 2022
NGM Bio Announces Topline Results from the CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration
Oct 16, 2022
NGM Bio to Host Conference Call to Discuss Topline Results from the CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
Sep 13, 2022
NGM Bio Presents Updated Preliminary Findings from the Ongoing Phase 1b Dose Escalation Trial of NGM120 in Combination with Gemcitabine and Nab-paclitaxel in Patients with Metastatic Pancreatic Cancer at AACR Special Conference: Pancreatic Cancer
Sep 06, 2022
NGM Bio Presents Updated Preliminary Findings for a Subgroup of Patients with Advanced Prostate Cancer from the Ongoing Phase 1a Dose Escalation Trial of NGM120 in Patients with Advanced Solid Tumors at the ESMO Annual Congress
Aug 15, 2022
NGM Bio Announces Presentations Featuring Updated Findings from the Ongoing Phase 1a Dose Escalation Trial of NGM120 in Patients with Advanced Solid Tumors at the European Society of Medical Oncology (ESMO) Annual Congress and the Ongoing Phase 1b Trial of NGM120 in Patients with Advanced Pancreatic Cancer at the American Association for Cancer Research (AACR) Special Conference: Pancreatic Cancer
Aug 04, 2022
NGM Bio Provides Business Highlights and Reports Second Quarter 2022 Financial Results
Jun 30, 2022
NGM Bio Appoints Siobhan Nolan Mangini to President and Chief Financial Officer
Jun 23, 2022
NGM Bio to Host the Final of Four Virtual R&D Events on June 29, 2022
Jun 02, 2022
NGM Bio to Participate in Upcoming Investor Conferences
May 24, 2022
NGM Bio to Host the Third of Four Virtual R&D Events on May 31, 2022
May 12, 2022
NGM Bio Announces Initiation of Phase 1/1b Clinical Study of NGM438 for the Treatment of Patients with Advanced Solid Tumors
May 05, 2022
NGM Bio Provides Business Highlights and Reports First Quarter 2022 Financial Results
Apr 20, 2022
NGM Bio to Host the Second of Four Virtual R&D Events on April 27, 2022
Apr 20, 2022
NGM Bio to Participate in Upcoming Investor Conferences
Apr 08, 2022
NGM Bio to Present Late-Breaking Preclinical Research at 2022 AACR Annual Meeting Supporting Development of its Myeloid Reprogramming Portfolio
Mar 31, 2022
NGM Bio Announces Initiation of Phase 1/1b Clinical Trial of NGM831 for the Treatment of Patients with Advanced Solid Tumors
Mar 21, 2022
NGM Bio to Host the First of Four Virtual R&D Events on March 30, 2022
Mar 08, 2022
NGM Bio Announces Oral and Late-Breaking Poster Presentations Supporting Its Myeloid Reprogramming Portfolio at Upcoming 2022 AACR Annual Meeting
Mar 01, 2022
NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2021 Financial Results
Feb 28, 2022
NGM Bio to Participate in the Cowen 42nd Annual Health Care Conference
Feb 07, 2022
NGM Bio’s NGM621 Receives Fast Track Designation from the FDA for the Treatment of Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
Jan 20, 2022
NGM Bio to Participate in Upcoming Investor Conferences
Jan 10, 2022
NGM Bio Outlines 2022 Strategic Priorities Across Its Portfolio of Clinical-Stage Oncology, Retinal and Liver and Metabolic Programs
Jan 06, 2022